[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (22,640)

Search Parameters:
Keywords = vascular

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 2687 KiB  
Article
A Robust Blood Vessel Segmentation Technique for Angiographic Images Employing Multi-Scale Filtering Approach
by Agne Paulauskaite-Taraseviciene, Julius Siaulys, Antanas Jankauskas and Gabriele Jakuskaite
J. Clin. Med. 2025, 14(2), 354; https://doi.org/10.3390/jcm14020354 - 8 Jan 2025
Abstract
Background: This study focuses on the critical task of blood vessel segmentation in medical image analysis, essential for diagnosing cardiovascular diseases and enabling effective treatment planning. Although deep learning architectures often produce very high segmentation results in medical images, coronary computed tomography [...] Read more.
Background: This study focuses on the critical task of blood vessel segmentation in medical image analysis, essential for diagnosing cardiovascular diseases and enabling effective treatment planning. Although deep learning architectures often produce very high segmentation results in medical images, coronary computed tomography angiography (CTA) images are more challenging than invasive coronary angiography (ICA) images due to noise and the complexity of vessel structures. Methods: Classical architectures for medical images, such as U-Net, achieve only moderate accuracy, with an average Dice score of 0.722. Results: This study introduces Morpho-U-Net, an enhanced U-Net architecture that integrates advanced morphological operations, including Gaussian blurring, thresholding, and morphological opening/closing, to improve vascular integrity, reduce noise, and achieve a higher Dice score of 0.9108, a precision of 0.9341, and a recall of 0.8872. These enhancements demonstrate superior robustness to noise and intricate vessel geometries. Conclusions: This pre-processing filter effectively reduces noise by grouping neighboring pixels with similar intensity values, allowing the model to focus on relevant anatomical structures, thus outperforming traditional methods in handling the challenges posed by CTA images. Full article
Show Figures

Figure 1

Figure 1
<p>Examples of precise contouring challenges in medical imaging of blood vessels.</p>
Full article ">Figure 2
<p>Visual comparison of ICA images (<b>a</b>) [<a href="#B26-jcm-14-00354" class="html-bibr">26</a>], (<b>b</b>) [<a href="#B30-jcm-14-00354" class="html-bibr">30</a>], (<b>c</b>) [<a href="#B15-jcm-14-00354" class="html-bibr">15</a>], (<b>d</b>) [<a href="#B2-jcm-14-00354" class="html-bibr">2</a>], (<b>e</b>) vs. CTA (<b>f</b>), emphasizing the high-resolution and detailed visualization typical of ICA, in contrast to the noise and contrast limitations of non-invasive CTA images.</p>
Full article ">Figure 3
<p>DuckNet Architecture Overview.</p>
Full article ">Figure 4
<p>RCA vessel images from the same patient, highlighting variations despite identical vessel anatomy and patient characteristics.</p>
Full article ">Figure 5
<p>Examples of (<b>a</b>) ground truth and (<b>b</b>) model predictions for coronary artery blood vessel segmentations.</p>
Full article ">Figure 6
<p>Instances of annotated vessels including initial and repeated annotation and their differences.</p>
Full article ">Figure 7
<p>Boundary inaccuracies representing minor differences between the ground truth and predicted masks.</p>
Full article ">Figure 8
<p>The pipeline of the proposed segmentation solution.</p>
Full article ">Figure 9
<p>Original image with (<b>a</b>) applied threshold, (<b>b</b>) region fill and threshold, (<b>c</b>) applied Frangi filter and (<b>d</b>) ground truth segmentation.</p>
Full article ">Figure 10
<p>Examples of segmentation results using Morpho-U-Net, resulting in DICE values of 0.927 for image (<b>A</b>) and 0.759 for image (<b>B</b>).</p>
Full article ">Figure 11
<p>Segmentation results for calcified, mixed, and non-calcified plaques.</p>
Full article ">Figure 12
<p>Examples of incomplete annotations.</p>
Full article ">
15 pages, 663 KiB  
Systematic Review
Graphene-Based Materials for Bone Regeneration in Dentistry: A Systematic Review of In Vitro Applications and Material Comparisons
by Azahara María Narváez-Romero, Francisco Javier Rodríguez-Lozano and María Pilar Pecci-Lloret
Nanomaterials 2025, 15(2), 88; https://doi.org/10.3390/nano15020088 - 8 Jan 2025
Abstract
Introduction: Graphene, a two-dimensional arrangement of carbon atoms, has drawn significant interest in medical research due to its unique properties. In the context of bone regeneration, graphene has shown several promising applications. Its robust structure, electrical conductivity, and biocompatibility make it an ideal [...] Read more.
Introduction: Graphene, a two-dimensional arrangement of carbon atoms, has drawn significant interest in medical research due to its unique properties. In the context of bone regeneration, graphene has shown several promising applications. Its robust structure, electrical conductivity, and biocompatibility make it an ideal candidate for enhancing bone tissue regeneration and repair processes. Studies have revealed that the presence of graphene can stimulate the proliferation and differentiation of bone cells, thereby promoting the formation of new bone tissue. Additionally, its ability to act as an effective carrier for growth factors and drugs allows controlled release, facilitating the engineering of specific tissues for bone regeneration. Aim: To assess the efficacy of graphene in enhancing bone regeneration through in vitro studies, identify key safety concerns, and propose directions for future research to optimize its clinical applicability. Materials and methods: The present systematic review was carried out using the PRISMA 2020 guideline. A first search was carried out on 20 November 2023 and was later updated on 14 February and 15 April 2024 in the databases of PubMed, Scopus, and Web of Science. Those in vitro studies published in English that evaluated the potential for bone regeneration with graphene in dentistry and also those which met the search terms were selected. Furthermore, the quality of the studies was assessed following the modified CONSORT checklist of in vitro studies on dental materials. Results: A total of 17 in vitro studies met the inclusion criteria. Among these, 12 showed increased osteoblast adhesion, proliferation, and differentiation, along with notable enhancements in mineralized matrix formation. Additionally, they exhibited a significant upregulation of osteogenic markers such as RUNX and COL1 (p < 0.05). However, the variability in methodologies and a lack of long-term assessments were noted as critical gaps. Conclusions: The evaluation of the efficacy and safety of graphene in bone regeneration in dentistry revealed significant potential. However, it is recognized that clinical implementation should be approached with caution, considering identified areas of improvement and suggestions for future research. Future studies should focus on standardized experimental designs, including in vivo studies to evaluate long-term safety, immune responses, and vascularization processes in realistic biological environments. Full article
(This article belongs to the Section Biology and Medicines)
Show Figures

Figure 1

Figure 1
<p>PRISMA 2020 flow diagram. Identification of studies via databases and registers.</p>
Full article ">
17 pages, 3331 KiB  
Case Report
EnBloc Resection of a Chordoma of the Thoracic Spine by “L”-Shaped Osteotomy for Spinal Canal Preservation
by Alessandro Gasbarrini, Stefano Pasini, Zhaozong Fu, Riccardo Ghermandi, Valerio Pipola, Mauro Gargiulo, Marco Innocenti and Stefano Boriani
J. Clin. Med. 2025, 14(2), 349; https://doi.org/10.3390/jcm14020349 - 8 Jan 2025
Abstract
Background/Objectives: EnBloc resections of bone tumors of the spine are very demanding as the target to achieve a tumor-free margin specimen (sometimes impossible due to the extracompartimental tumor extension) is sometimes conflicting with the integrity of neurological functions and spine stability. Methods [...] Read more.
Background/Objectives: EnBloc resections of bone tumors of the spine are very demanding as the target to achieve a tumor-free margin specimen (sometimes impossible due to the extracompartimental tumor extension) is sometimes conflicting with the integrity of neurological functions and spine stability. Methods: The surgical treatment of a huge multi-level chordoma of the thoracic spine with unusual extension is reported. Anteriorly, the tumor widely invaded the mediastinum and displaced the aorta; on the left side, it expanded in the subpleuric region; posteriorly, it was uncommonly distant 13 mm from the posterior wall. Results: EnBloc resection is largely performed for primary bone tumors of the spine and many reports have been published concerning brilliant solutions to difficult issues of surgical anatomy. One of the major challenges is still the compatibility between oncological and functional requirements. Conclusions: Oncological staging, careful imaging analysis, a multidisciplinary surgical team, and utilization of the most recent technologies like navigation and robotics have made an oncologically appropriate EnBloc resection of a multi-level chordoma of the thoracic spine possible without affecting the continuity of the spinal canal and without any involvement of its content by an original “L”-shaped osteotomy. Full article
(This article belongs to the Section Oncology)
Show Figures

Figure 1

Figure 1
<p>CT scan transverse image crossing T9 shows a lytic, moth-eaten change involving the anterior part of the T9 vertebral body with huge anterior mediastinal soft tissue partially surrounding and displacing the aorta. The transpedicular trocar track for biopsy is visible.</p>
Full article ">Figure 2
<p>(<b>a</b>) MR (T1_mDIXON_TSE) sagittal image shows the longitudinal tumor extension in the mediastinum originating from the vertebral body of T9 and invading the anterior part of T8 and T10 vertebral bodies without involvement of the disks. The disks T7–T8 and T10–T11 seem the best levels for cranial and caudal resection levels. (<b>b</b>) MR (T2W_mDixon_TSE FS) transverse image at T9 level clarifies that the aorta wall is not infiltrated and that there is a tumor-free zone from the posterior tumor margin and the posterior vertebral wall (according to the WBB staging system: layer A, only part of layer B, no layer C involvement). At this level (the largest tumor extension), the AP diameter of the T9 vertebral body is 28 mm, and the distance between the tumor and the posterior wall is 13 mm. The tumoral soft tissue expands on left side in the retro-pleural space to the level of the cost-transverse joint in T9 (sectors 8 to 4 according to the WBB staging system). (<b>c</b>) MR (T2W_mDixon_TSE FS) transverse image at T8: the tumors is much smaller in the mediastinum end and it is invading only the peripheral vertebral body cortex. The retro-pleural invasion on the left arrives at the level of the posterior longitudinal ligament (sectors 7 to 5 according to the WBB staging system). (<b>d</b>) MR (T2W_mDixon_TSE FS) transverse image at T10: the tumor invades the anterior part of the vertebral body; sectors 4 and 5 are not involved in the tumor.</p>
Full article ">Figure 2 Cont.
<p>(<b>a</b>) MR (T1_mDIXON_TSE) sagittal image shows the longitudinal tumor extension in the mediastinum originating from the vertebral body of T9 and invading the anterior part of T8 and T10 vertebral bodies without involvement of the disks. The disks T7–T8 and T10–T11 seem the best levels for cranial and caudal resection levels. (<b>b</b>) MR (T2W_mDixon_TSE FS) transverse image at T9 level clarifies that the aorta wall is not infiltrated and that there is a tumor-free zone from the posterior tumor margin and the posterior vertebral wall (according to the WBB staging system: layer A, only part of layer B, no layer C involvement). At this level (the largest tumor extension), the AP diameter of the T9 vertebral body is 28 mm, and the distance between the tumor and the posterior wall is 13 mm. The tumoral soft tissue expands on left side in the retro-pleural space to the level of the cost-transverse joint in T9 (sectors 8 to 4 according to the WBB staging system). (<b>c</b>) MR (T2W_mDixon_TSE FS) transverse image at T8: the tumors is much smaller in the mediastinum end and it is invading only the peripheral vertebral body cortex. The retro-pleural invasion on the left arrives at the level of the posterior longitudinal ligament (sectors 7 to 5 according to the WBB staging system). (<b>d</b>) MR (T2W_mDixon_TSE FS) transverse image at T10: the tumor invades the anterior part of the vertebral body; sectors 4 and 5 are not involved in the tumor.</p>
Full article ">Figure 3
<p>WBB planning of enbloc resection of the reported case. The tumor–free area between the posterior tumor margin and the posterior vertebral wall allows us to consider the possibility of saving the continuity of the spinal canal. Targeting the tumor-free margin and the integrity of the canal surgery should also be performed.</p>
Full article ">Figure 4
<p>Intraoperative image at the end of the left antero-lateral trans-pleural approach (at the seventh rib). The tumor mass can be seen covered by the parietal pleura as an effective margin. The descending aorta has been isolated and fully released without violations of the tumor mass. The segmental vessels are ligated at the origin. The anterior part of disks T7–T8 and T10–T11 has been excised. The left T7 segmental artery is prepared for planned anastomosis with the fibula feeding artery. Before the closure, a Gore–Tex mesh is positioned over the tumor mass for protection and to easily find the safely released peritumoral area during the posterior approach.</p>
Full article ">Figure 5
<p>Second stage. Patient in prone position. Posterior midline approach, and positioning of Carbon Fiber-Reinforced PEEK (CFRP) (Carboclear by Carbofix), screws in the pedicles of T5, T6, T7, T11, and T12. Excision of rib segments proximal to the spine at T8, T9, and T10; lateral release of the vertebral bodies reaching Gore–Tex mesh left over the released area during the anterior approach.</p>
Full article ">Figure 6
<p>(<b>a</b>) The Tomita saw is inserted left to right in the interspace T7–T8 inside the excised disk, leaving the posterior part of the disk intact. Its extremity is shifted along the right side of the spine up to disk T10–T11 (whose posterior half is similarly spared), where it is retrieved to the left side. (<b>b</b>) The anesthesiologist is asked to collapse the left lung in order to gain access to the lateral aspect of the vertebral bodies without injuring the parenchyma. By surgical robot (Excelsius by Globus) guidance, two percutaneous K wires are introduced on the coronal plane left to right, just below the superior endplate of T8 and just above the inferior endplate of T10, at a safe distance from the tumor and the vertebral posterior wall. Navigation is necessary in this phase because it is not possible to visualize the tumor inside of the vertebral body, and navigation is only able to guide the insertion, avoiding tumor violation. (<b>c</b>) The K–wires are introduced slightly dorsal to the plane of the Tomita saw to guide the osteotomy on the correct coronal plane to save the posterior part of the vertebral bodies without violating the tumor mass (arrows suggest the direction left–to–right).</p>
Full article ">Figure 6 Cont.
<p>(<b>a</b>) The Tomita saw is inserted left to right in the interspace T7–T8 inside the excised disk, leaving the posterior part of the disk intact. Its extremity is shifted along the right side of the spine up to disk T10–T11 (whose posterior half is similarly spared), where it is retrieved to the left side. (<b>b</b>) The anesthesiologist is asked to collapse the left lung in order to gain access to the lateral aspect of the vertebral bodies without injuring the parenchyma. By surgical robot (Excelsius by Globus) guidance, two percutaneous K wires are introduced on the coronal plane left to right, just below the superior endplate of T8 and just above the inferior endplate of T10, at a safe distance from the tumor and the vertebral posterior wall. Navigation is necessary in this phase because it is not possible to visualize the tumor inside of the vertebral body, and navigation is only able to guide the insertion, avoiding tumor violation. (<b>c</b>) The K–wires are introduced slightly dorsal to the plane of the Tomita saw to guide the osteotomy on the correct coronal plane to save the posterior part of the vertebral bodies without violating the tumor mass (arrows suggest the direction left–to–right).</p>
Full article ">Figure 7
<p>A screw is positioned in the left pedicle of T9 (uninvolved by the tumor) to stop the coronal osteotomy and to act as a pivot to start a sagittal osteotomy ending in “L-shaped” osteotomy. Again, screw insertion is guided by surgical navigation in order to avoid the end of the screw reaching the margin of the tumor.</p>
Full article ">Figure 8
<p>(<b>a</b>) The extremities of the Tomita saw are exteriorized by short incisions in order to cut on the desired coronal plan, running on the guide of the couple of K-wires. (<b>b</b>) Intraoperative picture of the Tsaw osteotomy on the coronal plane, always under navigation system control. To avoid damage to the soft tissues during the resection on the coronal plane, two plastic cannulas are used, which are positioned through the chest wall and inside which the saw is slid. In the image, while the first operator keeps the saw wire tensioned, the second operator positions the proximal cannula with Kocher pliers.</p>
Full article ">Figure 9
<p>(<b>a</b>) As soon as the saw comes into contact with the screw positioned in the left pedicle of T9, the handles of the saw are removed and the two extremities of the wire are slid back through the percutaneous paths. (<b>b</b>) The two extremities of the wire are then brought out vertically through the surgical wound. The handles are assembled on the wire again and repositioned along a sagittal direction. (<b>c</b>) Pulling up the handles, with the wire oriented in a vertical direction along the sagittal plane, the “L” osteotomy is completed at the T9 level, where the tumor grows laterally to sector 4. The T9 screw is therefore used first as a constraint to stop the saw along the resection in the coronal plane, and then as a guide for the osteotomy on the sagittal plane, providing the correct direction and avoiding a deviation of the saw.</p>
Full article ">Figure 9 Cont.
<p>(<b>a</b>) As soon as the saw comes into contact with the screw positioned in the left pedicle of T9, the handles of the saw are removed and the two extremities of the wire are slid back through the percutaneous paths. (<b>b</b>) The two extremities of the wire are then brought out vertically through the surgical wound. The handles are assembled on the wire again and repositioned along a sagittal direction. (<b>c</b>) Pulling up the handles, with the wire oriented in a vertical direction along the sagittal plane, the “L” osteotomy is completed at the T9 level, where the tumor grows laterally to sector 4. The T9 screw is therefore used first as a constraint to stop the saw along the resection in the coronal plane, and then as a guide for the osteotomy on the sagittal plane, providing the correct direction and avoiding a deviation of the saw.</p>
Full article ">Figure 10
<p>(<b>a</b>) By careful manual manipulations, the specimen was removed. (<b>b</b>) The tumor, covered by a thick margin of healthy tissue and still protected by the Gore-Tex mesh, was removed from the left side. The coronal resection of the vertebral bodies of T8 and T10 and the effect of the sagittal leg of the “L-shaped” osteotomy can be seen, allowing the inclusion of sectors 4 and 5 of T9 in the enbloc resection, corresponding to the lateral retropleural tumor extension (panel <b>A</b>) and to other angles of the excised specimen in panels (<b>B</b>,<b>C</b>).</p>
Full article ">Figure 11
<p>Post-operative CT scan image at the lower T9 level, distal to the sagittal leg of the osteotomy. As planned, the coronal osteotomy spared the circumference of the spinal canal and runs some millimeters from the tumor posterior margin. A Gore-Tex sheet is left, creating a new compartment from the mediastinum. Panel (<b>A</b>), axial section. Panels (<b>B</b>,<b>C</b>), coronal and sagittal sections showing the grafted fibula.</p>
Full article ">Figure 12
<p>Pathologist’s specimen of the resected vertebrae.</p>
Full article ">
15 pages, 469 KiB  
Review
Central Vascular Access Devices: Current Standards and Future Implications
by Benito Baldauf, Roberto Cemin, Jana Hummel, Hendrik Bonnemeier and Ojan Assadian
J. Vasc. Dis. 2025, 4(1), 3; https://doi.org/10.3390/jvd4010003 - 8 Jan 2025
Abstract
Background: Central venous access devices (CVADs) are crucial for various medical conditions, but pose risks, including catheter-related bloodstream infections (CRBSI). CRBSI increases comorbidity, mortality, and healthcare costs. Surveillance and evidence-based guidelines have successfully reduced CRBSI rates, although the COVID-19 pandemic has led to [...] Read more.
Background: Central venous access devices (CVADs) are crucial for various medical conditions, but pose risks, including catheter-related bloodstream infections (CRBSI). CRBSI increases comorbidity, mortality, and healthcare costs. Surveillance and evidence-based guidelines have successfully reduced CRBSI rates, although the COVID-19 pandemic has led to increased infection rates. Main body: This review explores strategies for reducing the incidence of CRBSI and examines factors contributing to variations in reported rates across developed countries. Highlighting the significant morbidity, mortality, and healthcare resource burden associated with CRBSI, the analysis delves into evidence-backed preventive measures. It discusses the impact of the COVID-19 pandemic on infection rates and proposes resilient strategies in response to these challenges. The review emphasises the importance of understanding CRBSI pathogenesis, patient, procedure, and device-related risk factors, and the implementation of evidence-guided algorithms and surveillance measures. Recommendations include the use of all-inclusive procedure packs, ultrasound-guided placement, daily dressing changes with antimicrobial treatment, and the use of antimicrobial locks. Conclusions: The review underscores the need for clear, concise algorithms adaptable to various healthcare settings and the scalability of infection prevention systems to ensure resilience. Full article
(This article belongs to the Section Peripheral Vascular Diseases)
24 pages, 8393 KiB  
Article
Reproducibility and Consistency of Isolation Protocols for Fibroblasts, Smooth Muscle Cells, and Epithelial Cells from the Human Vagina
by Jayson Sueters, Rogier Schipperheijn, Judith Huirne, Theo Smit and Zeliha Guler
Cells 2025, 14(2), 76; https://doi.org/10.3390/cells14020076 - 8 Jan 2025
Abstract
(1) Background: For the reconstruction of a human vagina, various surgical procedures are available that are often associated with complications due to their failure to mimic the physiology of the human vagina. We recently developed a vascularized, organ-specific matrix from healthy human vaginal [...] Read more.
(1) Background: For the reconstruction of a human vagina, various surgical procedures are available that are often associated with complications due to their failure to mimic the physiology of the human vagina. We recently developed a vascularized, organ-specific matrix from healthy human vaginal wall tissue with suitable biomechanical properties. A superior graft would require further extensive colonization with autologous vaginal cells to reduce complications upon implantation. However, reports on isolation of vaginal cells from biopsies are scarce, and published protocols rarely contain sufficient details. In this study, we aimed to examine protocols for inconsistencies and identify (where possible) the optimal protocol in terms of reproducibility and efficiency for isolation of human vaginal fibroblasts (FBs), epithelial cells (VECs), and smooth muscle cells (SMCs). Overall, this study aims to guide other researchers and aid future tissue engineering solutions that rely on autologous cells. (2) Methods: A total of 41 isolation protocols were tested: four protocols specific to FBs, 13 protocols for VECs, and 24 protocols for SMCs. Protocols were derived from published reports on cell isolation by enzymes, with exclusion criteria including the need for specialized equipment, surgical separation of tissue layers, or missing protocol details. Enzymatic digestion with collagenase-I, collagenase-IV, and dispase-II was used for isolation of VECs, collagenase-IV for isolation of SMCs, and collagenase-IA for isolation of FBs. Fluorescent immunostaining was applied to identify VECs with cytokeratin, SMCs with desmin, endothelial cells with UEA-1, and FBs with vimentin. Protocols were assessed based on (>95%) homogeneity, duplicate consistency, cell viability, and time to first passage. (3) Results: A total of 9 out of the 41 protocols resulted in isolation and expansion of vaginal FBs. This involved 1 out of 13 VEC protocols, 6 out of 24 SMC protocols, and 2 out of 2 FB protocols. Isolation of vaginal SMCs or VECs was not achieved. The best results were obtained after digestion with 0.1% collagenase-IV, where pure FB colonies formed with high cell viability. (4) Conclusions: Today, vaginoplasty is considered the gold standard for surgically creating a neovagina, despite its considerable drawbacks and limitations. Tissue-engineered solutions carry great potential as an alternative, but cell seeding is desired to prevent complications upon implantation of grafts. In this study, we examined isolation of human vaginal FBs, SMCs, and VECs, and identified the most efficient and reliable protocol for FBs. We further identified inconsistencies and irreproducible methods for isolation of VECs and SMCs. These findings aid the clinical translation of cell-based tissue engineering for the reconstruction and support of vaginas, fulfilling unmet medic needs. Full article
Show Figures

Figure 1

Figure 1
<p>Isolation protocols were tested for fibroblasts (blue), smooth muscle cells (green), and epithelial cells (orange) from human vaginal wall tissue. This illustration provides a schematic overview of the tested protocols.</p>
Full article ">Figure 2
<p>VEC-specific protocols were tested for digestion by a range of collagenase-I (col-I), collagenase-IV, and dispase-II (dis-II) concentrations. This resulted in (<b>A</b>) isolation of fibroblasts from the cell pellet after digestion with 1 mg/mL collagenase-I and (<b>B</b>) cell debris for use of high (2 or 4 mg/mL) dispase-II concentrations or combined use of dispase-II, collagenase-I, and collagenase-IV. DAPI = cell nuclei (blue), vimentin = fibroblasts (green), desmin = smooth muscle cells, and UEA-1 = endothelial cells (yellow).</p>
Full article ">Figure 3
<p>SMC-specific protocols were tested for digestion using a range of collagenase-IV (col-IV) concentrations. This resulted in isolation of FBs. With 0.1% col-IV and culturing in DMEM, FBs were retrieved from the (<b>A</b>) pellet, (<b>B</b>) supernatant (sup.), and (<b>C</b>) tissue. FBs were also retrieved through culturing in DMEM/F12 after isolation with (<b>D</b>) 0.2% col-IV from the tissue and (<b>E</b>) 0.5% collagenase-IV from the pellet. Digestion with 2 mg/mL col-IV resulted in FBs from (<b>F</b>) the pellet, with (<b>G</b>) the sporadic detection of muscle cells at quantities &lt;5%, and from (<b>H</b>) the supernatant, with (<b>I</b>) the sporadic detection of muscle and epithelial cells at quantities &lt;5%. DAPI = cell nuclei (blue), vimentin = fibroblasts (green), desmin = smooth muscle cells, and UEA-1 = endothelial cells (yellow).</p>
Full article ">Figure 4
<p>SMC-specific protocols were tested on diced sections from the smooth muscle layer and lamina propria. Digestion with various collagenase-I, collagenase-IV, and dispase-II concentrations was performed and tested for various media and temperatures. All protocols resulted in cell debris. Representative images illustrate digestion with 0.1% collagenase-IV (col-IV) from the cell pellet after culturing in (<b>A</b>) SMC-specific medium [S] at 32 °C or (<b>B</b>) at 37 °C, and in (<b>C</b>) DMEM/F12 medium [F] at 32 °C.</p>
Full article ">Figure 5
<p>SMC-specific protocols were tested for culturing under hypoxic conditions of 2% oxygen (low). Digestion with 0.1% collagenase-IV resulted in isolation of FBs from (<b>A</b>) the pellet and (<b>B</b>) the supernatant (sup.). Digestion with 2 mg/mL collagenase-IV resulted in FB isolation from (<b>C</b>) the supernatant. DAPI = cell nuclei (blue), vimentin = fibroblasts (green), desmin = smooth muscle cells, and UEA-1 = endothelial cells (yellow).</p>
Full article ">Figure 6
<p>SMC-specific protocols were tested for 0.1% collagenase-IV digestion with (<b>A</b>) alternative cell passaging. This resulted in the isolation of FBs after (<b>B</b>) 5 min of incubation in accutase and 24 h of cell attachment until the first medium refreshment. After 1 min trypsinization, FBs were isolated with cell attachment for (<b>C</b>) 3 h and (<b>D</b>) 24 h. For 3 min trypsinization, FBs formed with (<b>E</b>) 3 h and (<b>F</b>) 24 h cell attachment. For 5 min trypsinization, the same was observed with (<b>G</b>) 2 h, (<b>H</b>) 3 h, and (<b>I</b>) 24 h cell attachment. DAPI = cell nuclei (blue), vimentin = fibroblasts (green), desmin = smooth muscle cells, and UEA-1 = endothelial cells (yellow).</p>
Full article ">Figure 7
<p>FB-specific protocols were tested for digestion with 2 mg/mL collagenase-IA. FBs were isolated from the cell pellet with culturing in (<b>A</b>) DMEM and (<b>B</b>) DMEM/F12 (F). DAPI = cell nuclei (blue), vimentin = fibroblasts (green), desmin = smooth muscle cells, and UEA-1 = endothelial cells (yellow).</p>
Full article ">
18 pages, 2095 KiB  
Article
miR-1233-3p Inhibits Angiopoietin-1-Induced Endothelial Cell Survival, Migration, and Differentiation
by Veronica Sanchez, Sharon Harel, Anas Khalid Sa’ub, Dominique Mayaki and Sabah N. A. Hussain
Cells 2025, 14(2), 75; https://doi.org/10.3390/cells14020075 - 8 Jan 2025
Abstract
Angiopoietin-1 (Ang-1) and its receptor Tie-2 promote vascular integrity and angiogenesis. MicroRNAs (miRNAs) are involved in the regulation of many cellular functions, including endothelial cell (EC) survival, proliferation, and differentiation. Several reports indicate that these effects of miRNAs on EC functions are mediated [...] Read more.
Angiopoietin-1 (Ang-1) and its receptor Tie-2 promote vascular integrity and angiogenesis. MicroRNAs (miRNAs) are involved in the regulation of many cellular functions, including endothelial cell (EC) survival, proliferation, and differentiation. Several reports indicate that these effects of miRNAs on EC functions are mediated through the modulation of angiogenesis factor signaling including that of vascular endothelial growth factor (VEGF). To date, very little is known about the roles played by miRNAs in the signaling and angiogenesis promoted by the Ang-1–Tie-2 receptor axis. Our high-throughput screening of miRNAs regulated by Ang-1 exposure in human umbilical vein endothelial cells (HUVECs) has identified miR-1233-3p as a mature miRNA whose cellular levels are significantly downregulated in response to Ang-1 exposure. The expression of miR-1233-3p in these cells is also downregulated by other angiogenesis factors including VEGF, fibroblast growth factor 2 (FGF-2), transforming growth factor β (TGFβ), and angiopoietin-2 (Ang-2). The overexpression of miR-1233-3p in HUVECs using specific mimics significantly attenuated cell survival, migration, and capillary-like tube formation, and promoted apoptosis. Moreover, miR-1233-3p overexpression resulted in reversal of the anti-apoptotic, pro-migration, and pro-differentiation effects of Ang-1. Biotinylated miRNA pull-down assays showed that p53 and DNA damage-regulated 1 (PDRG1) is a direct target of miR-1233-3p in HUVECs. The exposure of HUVECs to Ang-1, angiopoietin-2 (Ang-2), fibroblast growth factor 2 (FGF2), vascular endothelial growth factor (VEGF), or transforming growth factor β (TGFβ) triggers the regulation of PDRG1 expression. This study highlights that miR-1233-3p exerts inhibitory effects on Ang-1-induced survival, migration, and the differentiation of cultured ECs. Full article
(This article belongs to the Collection microRNAs in Health and Diseases)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Ang-1 regulates miR-1233-3p in HUVECs. (<b>A</b>,<b>B</b>) miR-1233-3p levels measured in HUVECs exposed for 2, 4, 6, 10, 24, 48, and 72 h to PBS or Ang-1 (300 ng/mL). (<b>C</b>) Expression of GOLGA8A mRNA in HUVECs exposed for 2, 4, 6, and 10 h to PBS or Ang-1. (<b>D</b>) Levels of miR-1233-3p in HUVEC exosomes after 24 h of PBS or Ang-1 (300 ng/mL) treatment. (<b>E</b>) Expression levels of miR-1233-3p in HUVECs treated with control or Tie-2 blocking antibodies and incubated with PBS or Ang-1 (300 ng/mL) for 24 h. (<b>F</b>) Expression of miR-1233-3p in HUVECs treated PBS or growth factors (TGFβ, Ang-2, VEGF and FGF-2) for 24 h. Values are expressed as means± SEM and are expressed as fold change from PBS. * <span class="html-italic">p</span> &lt; 0.05, compared with PBS.</p>
Full article ">Figure 2
<p>Regulation of cell survival and migration by miR-1233-3p and Ang-1. (<b>A</b>,<b>B</b>) HUVECs transfected with control or miR-1233-3p mimics were maintained in complete medium, basic medium+FBS, or basic medium + Ang-1. (<b>C</b>,<b>D</b>) HUVECs transfected with control or miR-1233-3p inhibitors were maintained in complete medium, basic medium+ FBS, or basic medium + Ang-1. (<b>E</b>,<b>F</b>) Percentage wound healing and representative images of HUVECs transfected with control or miR-1233-3p mimics and treated with PBS or Ang-1 (300 ng/mL) for 8 h. (<b>G</b>) Percentage wound healing of HUVECs transfected with control or miR-1233-3p inhibitors and treated with PBS or Ang-1 (300 ng/mL) for 8 h. Values are means ± SEM. * <span class="html-italic">p</span> &lt; 0.05, compared to PBS alone. # <span class="html-italic">p</span> &lt; 0.05, compared to basal medium. ϕ <span class="html-italic">p</span> &lt; 0.05, compared to cells transfected with control mimic or control inhibitor. Scale bar in panel F = 100 µm.</p>
Full article ">Figure 3
<p>Effects of miR-1233-3p on EC differentiation and proliferation by miR-1233-3p. (<b>A</b>) The average tube lengths of capillary-like tube formation in HUVECs transfected with the control and miR-1233-3p mimic in the presence of PBS or Ang-1. Values are means ± SEM. (<b>B</b>) Representative images of capillary-like tube formation in cells transfected with control mimic in the presence of PBS (i) or Ang-1 (ii). Also shown are HUVECs transfected with the miR-1233-3p mimic in the presence of PBS (iii) or Ang-1 (iv). (<b>C</b>,<b>D</b>) The average and total tube lengths of cells transfected with the control and miR-1233-3p inhibitors in the presence of FBS or Ang-1. (<b>E</b>,<b>F</b>) BrdU incorporation in HUVECs transfected with the control and miR-1233-3p mimics or inhibitors in the presence of PBS. Values are means ± SEM. * <span class="html-italic">p</span> &lt; 0.05, compared to PBS alone. ϕ <span class="html-italic">p</span> &lt; 0.05, compared to cells transfected with control mimic or control inhibitor. Scale bar in panel B = 200 µm.</p>
Full article ">Figure 4
<p>Identification of PDRG1 as miR-1233-3p target. (<b>A</b>) Venn diagram displaying in silico predicted targets of miR1233-3p as computed by DIANA, TargetScan, and miRDB algorithms. (<b>B</b>) PDRG1 mRNA expression in HUVECs transfected with miR-1233-3p mimic or inhibitor and their respective controls (denoted by dotted line). Values are expressed as fold change from control mimic and inhibitor. (<b>C</b>,<b>D</b>) Representative immunoblots of PDRG1 and β-ACTIN proteins and quantification of PDRG1 protein levels in HUVECs transfected with control or miR-1233-3p mimics. Values are means± SEM and are expressed as fold change from control mimic. (<b>E</b>,<b>F</b>) Representative immunoblots of PDRG1 and β-ACTIN proteins and quantification of PDRG1 protein levels in HUVECs transfected with control or miR-1233-3p inhibitors. Values are means± SEM and are expressed as fold change from control inhibitor. * <span class="html-italic">p</span> &lt; 0.05, compared to control mimic or inhibitor.</p>
Full article ">Figure 5
<p>PDRG1 is a direct target of miR-1233-3p. (<b>A</b>) A schematic representation of the sequence alignment of miR-1233-3p and the predicted binding sites according to the DIANA algorithm on the 3′ UTR of PDRG1 mRNA. The numbers between the brackets indicate the nucleotide number of 3’ UTR of PDRG1. (<b>B</b>–<b>D</b>) Biotinylated miR-1233-3p pull-down assays. (<b>B</b>,<b>C</b>) Illustrate the levels of miR-1233-3p and U6 RNA after the transfection of 50 nM biotinylated control or miR mimics in HUVECs. Values are expressed as a fold change from the control mimic. (<b>D</b>) Shows mRNA levels of PDRG1, HOXB3, and ZFP91 detected with qPCR in the pull-down materials isolated from HUVECs transfected with the biotinylated control or miR-1233 mimics. Values are expressed as a fold change from the control mimic. (<b>E</b>) The levels of PDRG1, HOXB3, and ZFP91 mRNA in the total input mRNAs measured by qPCR. Enrichment was calculated as follows: X = miR pull-down/control pull-down. Y = miR input/control input. Fold binding = X/Y. Values are expressed as means ± SEM. * <span class="html-italic">p</span> &lt; 0.05, compared to the biotinylated control mimic.</p>
Full article ">Figure 6
<p>Ang-1 regulates PDRG1 expression. (<b>A</b>,<b>B</b>) PDRG1 mRNA levels in HUVECs treated with PBS or Ang-1 (300 ng/mL) for 2, 4, 6, 10, 12, 24, 48, and 72 h. (<b>C</b>) Representative immunoblots of PDRG1 protein in HUVECs exposed to PBS or Ang-1 for 3, 6, 12, and 24 h. (<b>D</b>) Mean values of PDRG1 protein levels in HUVECs exposed to PBS or Ang-1 for 24 h. (<b>E</b>,<b>F</b>) Representative immunoblots of PDRG1 and β-ACTIN proteins and mean values of PDRG1 protein levels in HUVECs exposed for 24 h to PBS, Ang-2 (300 ng/mL), FGF-2 (10 ng/mL), or VEGF (40 ng/mL). Values are expressed as means± SEM and are expressed as a fold change from PBS. * <span class="html-italic">p</span> &lt; 0.05, compared to PBS.</p>
Full article ">
20 pages, 15568 KiB  
Article
Line-Field Confocal Optical Coherence Tomography of Plaque Psoriasis Under IL-17 Inhibitor Therapy: Artificial Intelligence-Supported Analysis
by Hanna B. Wirsching, Oliver J. Mayer, Sophia Schlingmann, Janis R. Thamm, Stefan Schiele, Anna Rubeck, Wera Heinz, Julia Welzel and Sandra Schuh
Appl. Sci. 2025, 15(2), 535; https://doi.org/10.3390/app15020535 - 8 Jan 2025
Abstract
To date, therapeutic responses in plaque psoriasis are evaluated with clinical scores. No objective examination has been established. A recently developed non-invasive imaging tool, line-field confocal optical coherence tomography (LC-OCT), enables the in vivo live imaging of skin changes in psoriasis under therapy. [...] Read more.
To date, therapeutic responses in plaque psoriasis are evaluated with clinical scores. No objective examination has been established. A recently developed non-invasive imaging tool, line-field confocal optical coherence tomography (LC-OCT), enables the in vivo live imaging of skin changes in psoriasis under therapy. The aim of this study was to measure therapeutic response clinically and with LC-OCT, comparing the subjectively scored epidermal changes with an AI-supported analysis. This prospective, observational study included 12 patients with psoriasis starting a systemic treatment with IL-17 inhibitors (secukinumab, ixekizumab, and bimekizumab). LC-OCT and clinical assessment with a local psoriasis and severity index of the study plaque and a control area were performed before the initiation of therapy as well as after 4 and 12 weeks of treatment. A manual and AI-supported measurement of the thickness of epidermis, stratum corneum, and undulation of the dermo-epidermal junction was carried out. Acanthosis and hyperkeratosis showed a significant reduction under treatment. AI-supported calculations were compared to subjective measurements showing good reliability with high correlation. AI-supported analysis of vascular changes may serve as a prognostic and therapeutic response marker in the future. Full article
(This article belongs to the Special Issue Applications of Artificial Intelligence in Biomedical Diagnosis)
Show Figures

Figure 1

Figure 1
<p>(<b>a</b>) V0 SP right elbow: vertical (top) and horizontal (bottom). Line-field confocal optical coherence tomography picture (horizontal image size: 1.2 mm × 0.5 mm; vertical image size: 1.2 mm × 0.4 mm) of SP before start of therapy (LPSI 7) with hyperkeratosis (yellow line), parakeratosis (red arrows), dilated vessels (yellow arrows) in elongated rete ridges, acanthosis (red line), and bright inflammatory cells in the epidermis (red arrowheads); accompanying dermatoscopic picture (bottom right corner, image size: 1.2 mm × 0.5 mm) with scales and dotted vessels (blue arrows). Abbreviations: V0 = visit 0 before start of treatment, SP = study plaque, LPSI = local psoriasis severity index. (<b>b</b>) V1 SP: right elbow: vertical (top) and horizontal (bottom). Line-field confocal optical coherence tomography (horizontal image size: 1.2 mm × 0.5 mm; vertical image size: 1.2 mm × 0.4 mm) of SP after 4 weeks of therapy (LPSI 4), less hyperkeratosis (yellow line) and parakeratosis (red arrows), dilated vessels (yellow arrows) in elongated rete ridges, less acanthosis (red line), and bright inflammatory cells in the epidermis (red arrowheads); accompanying dermatoscopic picture (bottom right corner, image size: 1.2 mm × 0.5 mm) with no more scales and only very few dotted vessels (blue arrows). Abbreviations: V1 = visit 1 after 4 weeks of treatment, SP = study plaque, LPSI = local psoriasis severity index. (<b>c</b>) V2 SP: right elbow: vertical (top) and horizontal (bottom). Line-field confocal optical coherence tomography (horizontal image size: 1.2 mm × 0.5 mm; vertical image size: 1.2 mm × 0.4 mm) of SP after 12 weeks of therapy: clinically, skin almost completely cleared (LPSI of 1, only minimal erythema left), no more hyperkeratosis (yellow line indicating stratum corneum) or parakeratosis, dilated vessels (yellow arrows) without elongated rete ridges, no more acanthosis (red line), and a few bright inflammatory cells in the epidermis (red arrowheads) and pigmented keratinocytes around the dermal papillae (blue arrowheads); accompanying dermatoscopic picture (bottom right corner, image size: 1.2 mm × 0.5 mm) with no more scales and a few dotted vessels (blue arrows, purple pigment as skin marker particles in between). Abbreviations: V2 = visit 2 after 12 weeks of treatment, SP = study plaque, LPSI = local psoriasis severity index.</p>
Full article ">Figure 1 Cont.
<p>(<b>a</b>) V0 SP right elbow: vertical (top) and horizontal (bottom). Line-field confocal optical coherence tomography picture (horizontal image size: 1.2 mm × 0.5 mm; vertical image size: 1.2 mm × 0.4 mm) of SP before start of therapy (LPSI 7) with hyperkeratosis (yellow line), parakeratosis (red arrows), dilated vessels (yellow arrows) in elongated rete ridges, acanthosis (red line), and bright inflammatory cells in the epidermis (red arrowheads); accompanying dermatoscopic picture (bottom right corner, image size: 1.2 mm × 0.5 mm) with scales and dotted vessels (blue arrows). Abbreviations: V0 = visit 0 before start of treatment, SP = study plaque, LPSI = local psoriasis severity index. (<b>b</b>) V1 SP: right elbow: vertical (top) and horizontal (bottom). Line-field confocal optical coherence tomography (horizontal image size: 1.2 mm × 0.5 mm; vertical image size: 1.2 mm × 0.4 mm) of SP after 4 weeks of therapy (LPSI 4), less hyperkeratosis (yellow line) and parakeratosis (red arrows), dilated vessels (yellow arrows) in elongated rete ridges, less acanthosis (red line), and bright inflammatory cells in the epidermis (red arrowheads); accompanying dermatoscopic picture (bottom right corner, image size: 1.2 mm × 0.5 mm) with no more scales and only very few dotted vessels (blue arrows). Abbreviations: V1 = visit 1 after 4 weeks of treatment, SP = study plaque, LPSI = local psoriasis severity index. (<b>c</b>) V2 SP: right elbow: vertical (top) and horizontal (bottom). Line-field confocal optical coherence tomography (horizontal image size: 1.2 mm × 0.5 mm; vertical image size: 1.2 mm × 0.4 mm) of SP after 12 weeks of therapy: clinically, skin almost completely cleared (LPSI of 1, only minimal erythema left), no more hyperkeratosis (yellow line indicating stratum corneum) or parakeratosis, dilated vessels (yellow arrows) without elongated rete ridges, no more acanthosis (red line), and a few bright inflammatory cells in the epidermis (red arrowheads) and pigmented keratinocytes around the dermal papillae (blue arrowheads); accompanying dermatoscopic picture (bottom right corner, image size: 1.2 mm × 0.5 mm) with no more scales and a few dotted vessels (blue arrows, purple pigment as skin marker particles in between). Abbreviations: V2 = visit 2 after 12 weeks of treatment, SP = study plaque, LPSI = local psoriasis severity index.</p>
Full article ">Figure 2
<p>The artificial intelligence (AI) model segmented line-field confocal optical coherence tomography stacks (only the vertical view within the 3D stack depicted here, LC-OCT image size: 1.2 mm × 0.4 mm) of study plaque (left side) and control area (right side). Blue line = skin surface; red line = boundary between stratum corneum and stratum granulosum/living epidermis; green line = before dermo-epidermal junction. V0 = before therapy, V1 = after 4 weeks of therapy, V2 = after 12 weeks of therapy.</p>
Full article ">Figure 3
<p>Three-dimensional (3D) line-field confocal optical coherence tomography (vertical image size: 1.2 mm × 0.4 mm; 3D image size: 1.2 × 0.5 × 0.5 mm<sup>3</sup>) stack with reconstruction of the artificial intelligence (AI) model-generated segmentation of skin layers (blue = skin surface, red = boundary between stratum corneum and stratum granulosum, green = dermo-epidermal junction).</p>
Full article ">Figure 4
<p>(<b>a</b>) Reduction in PASI score under therapy; (<b>b</b>) reduction in DLQI score under therapy. PASI = psoriasis area and severity index; DLQI = quality of life index. The thick horizontal line within each boxplot corresponds to the median.</p>
Full article ">Figure 5
<p>(<b>a</b>) Reduction in LPSI score for all patients at each study visit (V0 before therapy, V1 after 4 weeks, V2 after 12 weeks of therapy). (<b>b</b>) First patient’s clinical pictures of SP on the left elbow before therapy (b-i, LPSI 6), after 4 weeks (b-ii, LPSI 2), and 12 weeks (b-iii, LPSI 2) after therapy; second patient’s clinical pictures of the SP left ventral thigh before therapy (b-iv, LPSI 9), after 4 weeks of therapy (b-v, LPSI 6), and after 12 weeks of therapy (b-vi, LPSI 1). LPSI = local psoriasis severity index. SP = study plaque. Thick horizontal line in the boxplot = median.</p>
Full article ">Figure 6
<p>(<b>a</b>) Manual measurement of epidermal thickness/acanthosis (in µm) in the SP (orange) and CoA (blue) before (V0) and under therapy (V1 after 4 weeks, V2 after 12 weeks). (<b>b</b>) Manual measurement of stratum corneum/hyperkeratosis (in µm) in the SP (orange) and CoA (blue) before (V0) and under therapy (V1 after 4 weeks, V2 after 12 weeks). SP = study plaque, CoA = control area, healthy control area in similar localization, µm = micrometer. Thick horizontal line in the boxplots = median.</p>
Full article ">Figure 7
<p>(<b>a</b>) AI model measurement of epidermal thickness/acanthosis (in µm) in the SP (orange) and CoA (blue) before (V0) and under therapy (V1 after 4 weeks, V2 after 12 weeks); (<b>b</b>) AI-model measurement of stratum corneum/hyperkeratosis (in µm) in the SP (orange) and CoA (blue) before (V0) and under therapy (V1 after 4 weeks, V2 after 12 weeks). SP = study plaque, CoA = control area; µm = micrometer.</p>
Full article ">Figure 8
<p>(<b>a</b>) Correlation between artificial intelligence (AI) and subjectively scored measurements for the stratum corneum thickness comparing all lesions and timepoints; (<b>b</b>) correlation between AI-supported and subjectively scored measurements of the epidermis thickness in µm, analyzing all lesions and timepoints. Black line = indicating dot position for perfect match of the measurements.</p>
Full article ">Figure 9
<p>(<b>a</b>) DEJ undulation in percentage in the SP and CoA before therapy (V0) as well as after 4 weeks of treatment (V1) and 12 weeks of treatment (V2); (<b>b</b>) difference in DEJ undulation between SP and CoA before therapy (V0) as well es in the course of treatment (V1, V2). SP = study plaque; CoA = control area, DEJ = dermo-epidermal junction.</p>
Full article ">Figure 10
<p>Depiction of vessels at V0 (‘Before’) and V2 (‘After’ 12 weeks of therapy) via line-field confocal optical coherence tomography (deepLive<sup>TM</sup>, Paris, France) (upper image part of vertical and horizontal view (vertical image size: LC-OCT image size: 1.2 mm × 0.4 mm; horizontal image size: 1.2 mm × 0.5 mm), blue line corresponding to the height of the depicted horizontal image within the 3D stack, purple line corresponding to the location of the depicted vertical image within the 3D stack, accompanying dermoscopy picture (image size: 1.2 mm × 0.5 mm), bottom minimal rendering of 3D block for better visualization of vessels (3D image size: 1.2 × 0.5 × 0.5 mm<sup>3</sup>)). Initially, there were highly increased vasculature and typical glomerular vessels in elongated rete ridges; after 12 weeks of therapy, despite clinical remission there is a persistence of augmented vascularization; and now, more reticular vessels can be seen but the ends of the vessels still have a glomerular aspect (for a video animation of the vasculature, please see <a href="#app1-applsci-15-00535" class="html-app">S1 and S2 in the Supplementary Section</a>).</p>
Full article ">
10 pages, 1187 KiB  
Article
Circulating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and Without Venous Thromboembolism
by Valentina Lami, Dario Nieri, Marta Pagnini, Mario Gattini, Claudia Donati, Mariella De Santis, Alessandro Cipriano, Erica Bazzan, Andrea Sbrana, Alessandro Celi and Tommaso Neri
Biomolecules 2025, 15(1), 83; https://doi.org/10.3390/biom15010083 - 8 Jan 2025
Abstract
Cancer is characterized by chronic inflammation and hypercoagulability, with an excess of venous thromboembolism (VTE). Tissue factor, the initiator of blood coagulation, circulates associated with extracellular vesicles (EV-TF). Studies investigating EV-TF between cancer-associated and non-cancer-associated VTE are lacking. We therefore compared EV-TF in [...] Read more.
Cancer is characterized by chronic inflammation and hypercoagulability, with an excess of venous thromboembolism (VTE). Tissue factor, the initiator of blood coagulation, circulates associated with extracellular vesicles (EV-TF). Studies investigating EV-TF between cancer-associated and non-cancer-associated VTE are lacking. We therefore compared EV-TF in unprovoked VTE (U-VTE), cancer-associated VTE (C-VTE), and cancer without VTE (C-w/o VTE). We also investigated interleukin-6 (IL-6) levels between the same groups. The final population included 68 patients (U-VTE: n = 15; C-VTE: n = 24; C-w/o VTE: n = 29). All patients with VTE were enrolled within 48 h of diagnosis; non-VTE patients were recruited in the oncologic outpatient services. EV were isolated by differential centrifugation from 4 mL of peripheral blood; the final EV pellet (16,000× g for 45 min) was resuspended in 100 μL saline and tested for TF using a one-step clotting assay. There was a statistically significant difference for higher EV-TF in C-VTE and C-w/o VTE compared to U-VTE (p = 0.024; Kruskal–Wallis test). There was no significant difference between C-VTE and C-w/o VTE. Moreover, we did not find any difference in IL-6 levels. These preliminary data suggest that cancer represents, per se, a strong driver of EV-TF generation. Full article
(This article belongs to the Special Issue Extracellular Vesicles as Biomarkers of Diseases)
Show Figures

Figure 1

Figure 1
<p>Schematic representation of tissue factor role in cancer. TF: tissue factor; FVII: coagulation factor VII; FVIIa: active FVII; FX: coagulation factor X; FXa: active FX; EV: extracellular vesicles. PAR: protease-activated receptor.</p>
Full article ">Figure 2
<p>Evaluation of (<b>A</b>) EV-TF (pg/mL), (<b>B</b>) total TF (pg/mL), and (<b>C</b>) IL-6 (pg/mL) in the three study groups: U-VTE, C-VTE and C-w/o VTE. * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.005; *** <span class="html-italic">p</span> &lt; 0.001; ns: not significant. EV-TF: extracellular vesicles-associated tissue factor activity; TF: tissue factor; IL-6: interleukin-6; U-VTE: unprovoked venous thromboembolism; C-VTE: venous thromboembolism with active cancer; C-w/o VTE: active cancer without venous thromboembolism.</p>
Full article ">Figure 3
<p>Direct correlation in the whole study population. (<b>A</b>) EV-TF and total TF (Spearman rho 0.491, <span class="html-italic">p</span> &lt; 0.001), (<b>B</b>) IL-6 and EV-TF (Spearman rho 0.380, <span class="html-italic">p</span> = 0.001) and (<b>C</b>) IL-6 and total TF (Spearman rho 0.405, <span class="html-italic">p</span> &lt; 0.001). U-VTE = empty circles; C-w/o VTE = triangles; C-VTE = filled circles; EV-TF: extracellular vesicles-associated tissue factor activity; TF: tissue factor; IL-6: interleukin-6; U-VTE: unprovoked venous thromboembolism; C-VTE: venous thromboembolism with active cancer; C-w/o VTE: active cancer without venous thromboembolism.</p>
Full article ">
22 pages, 2440 KiB  
Review
Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective
by Yan Ma, Mandy O. J. Grootaert and Raj N. Sewduth
J. Xenobiot. 2025, 15(1), 9; https://doi.org/10.3390/jox15010009 - 8 Jan 2025
Abstract
Chemotherapy-induced cardiotoxicity is a critical issue in cardio-oncology, as cancer treatments often lead to severe cardiovascular complications. Approximately 10% of cancer patients succumb to cardiovascular problems, with lung cancer patients frequently experiencing arrhythmias, cardiac failure, tamponade, and cardiac metastasis. The cardiotoxic effects of [...] Read more.
Chemotherapy-induced cardiotoxicity is a critical issue in cardio-oncology, as cancer treatments often lead to severe cardiovascular complications. Approximately 10% of cancer patients succumb to cardiovascular problems, with lung cancer patients frequently experiencing arrhythmias, cardiac failure, tamponade, and cardiac metastasis. The cardiotoxic effects of anti-cancer treatments manifest at both cellular and tissue levels, causing deformation of cardiomyocytes, leading to contractility issues and fibrosis. Repeated irradiation and chemotherapy increase the risk of valvular, pericardial, or myocardial diseases. Multi-OMICs analyses reveal that targeting specific pathways as well as specific protein modifications, such as ubiquitination and phosphorylation, could offer potential therapeutic alternatives to current treatments, including Angiotensin converting enzymes (ACE) inhibitors and beta-blockers that mitigate symptoms but do not prevent cardiomyocyte death, highlighting the need for more effective therapies to manage cardiovascular defects in cancer survivors. This review explores the xenobiotic nature of chemotherapy agents and their impact on cardiovascular health, aiming to identify novel biomarkers and therapeutic targets to mitigate cardiotoxicity. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Cardiovascular events in cancer patients after chemotherapy or radiotherapy (<b>A</b>,<b>B</b>) (adapted from [<a href="#B17-jox-15-00009" class="html-bibr">17</a>]) as well as relevance of multi-OMICs analyses to improve their understanding (<b>C</b>).</p>
Full article ">Figure 2
<p>TrancriptOMICs analysis of cardiac disease initiation in cardiomyocytes (<b>A</b>) Pathway analysis of RNA sequencing from isolated cardiomyocytes after exposition to doxorubicin (GSE226116) comparing differentially expressed genes (q value &lt; 0.005) using ENRICHR (Hallmark analysis). N = 3. Odds ratios are graphed, and the bars sorted from the most significant adjusted <span class="html-italic">p</span> value. (<b>B</b>) CRISPR screen comparing inhibited sgRNA (CRISPRi) when comparing the Doxocyclin-treated vs. Vehicle IPSC-derived cardiomyocytes conditions (Dataset: GSE276161). Positively and negatively enriched sgRNAs in red and blue respectively, grey indicate sgRNAs that do not show effects. (<b>C</b>,<b>D</b>) Reactome analysis performed on the positively and negatively enriched sgRNAs. The color of the dot corresponds to the adjusted <span class="html-italic">p</span>-value for each pathway (green for the most significant adjusted <span class="html-italic">p</span> value to dark blue for the less significant ones) and the size of the dot corresponds to the number of inhibited sgRNA for each group.</p>
Full article ">Figure 3
<p>Transcriptomic analysis of cardiac disease initiation in endothelial cells. (<b>A</b>,<b>B</b>) Pathway analysis of RNA sequencing from isolated cardiac ECs after exposition to doxorubicin (GSE226116) comparing differentially expressed genes (q value &lt; 0.005) using ENRICHR N = 3. Odds ratios are graphed, and the bars are sorted from the most significant corrected <span class="html-italic">p</span> value. TRRUST analysis and Wikipathways analysis respectively.</p>
Full article ">Figure 4
<p>Transcriptomic analysis of cardiac disease initiation upon Sorafenib treatment in cardiomyocytes adapted from Series GSE222642 comparing differentially expressed genes (q value &lt; 0.005), where male rats were gavaged with 50 mg/kg sorafenib (heart tissues collected at 14 days after treatment). ENCODE analysis (<b>A</b>) and Wikipathways analysis (<b>B</b>) respectively (ENRICHR, software developed by Ma’ayan lab, Computational Systems Biology, New York, NY, USA).</p>
Full article ">Figure 5
<p>Transcriptomic analysis of cardiac disease initiation upon Indisulam treatment in cardiomyocytes from Query DataSets for GSE213311 comparing differentially expressed genes (q value &lt; 0.005), RNA-seq analysis on cardiomyocytes treated with vehicle or indisulam. ENCODE analysis (<b>A</b>) and Wikipathways analysis (<b>B</b>) respectively (ENRICHR, Ma’ayan lab).</p>
Full article ">Figure 6
<p>Transcriptomic analysis of cardiac disease initiation upon Trastuzumab treatment in cardiomyocytes adapted from GSE264120 comparing differentially expressed genes (q value &lt; 0.005), ENCODE analysis (<b>A</b>) and MCF7 GEO UP signatures analysis (<b>B</b>) respectively (ENRICHR, Ma’ayan lab).</p>
Full article ">Figure 7
<p>Transcriptomic analysis of cardiac disease initiation in rats upon 5-FU treatment in cardiomyocytes adapted from GSE166957 comparing differentially expressed genes (q value &lt; 0.005), TRRUST analysis (<b>A</b>) and Wikipathways analysis (<b>B</b>) respectively (ENRICHR, Ma’ayan lab).</p>
Full article ">Figure 8
<p>Transcriptomic analysis of cardiomyocyte response to doxorubicin in mice with OTUB1 heterozygous knockout according to Data obtained from GSE240959 and comparing differentially expressed genes (q value &lt; 0.005), using ENRICHR. Odds ratios are graphed, and corrected <span class="html-italic">p</span> values are indicated. TRRUST analysis (<b>A</b>) and Wikipathways analysis (<b>B</b>) respectively.</p>
Full article ">Figure 9
<p>Transcriptomic analysis of cardiomyocyte response to doxorubicin in mice with ADAM17 knockout. Data obtained from GSE276325 comparing differentially expressed genes (q value &lt; 0.005), Odds ratios are graphed, and bars are sorted from the most significant corrected <span class="html-italic">p</span>-value. TRRUST analysis (<b>A</b>) and Wikipathways analysis (<b>B</b>) respectively.</p>
Full article ">
13 pages, 1997 KiB  
Systematic Review
Optimal Timing and Treatment Modalities of Arytenoid Dislocation and Subluxation: A Meta-Analysis
by Andrea Frosolini, Valeria Caragli, Giulio Badin, Leonardo Franz, Patrizia Bartolotta, Andrea Lovato, Luca Vedovelli, Elisabetta Genovese, Cosimo de Filippis and Gino Marioni
Medicina 2025, 61(1), 92; https://doi.org/10.3390/medicina61010092 - 8 Jan 2025
Viewed by 47
Abstract
Background and Objective: Arytenoid dislocation (AD) and subluxation (AS) impact vocal fold mobility, potentially affecting the quality of life. Their management, including the timing and modality of treatment, remains a subject of research. Our primary objective was to assess and compare the [...] Read more.
Background and Objective: Arytenoid dislocation (AD) and subluxation (AS) impact vocal fold mobility, potentially affecting the quality of life. Their management, including the timing and modality of treatment, remains a subject of research. Our primary objective was to assess and compare the available treatment strategies for AS and AD. Material and methods: the protocol was registered on PROSPERO (CRD42023407521). Manuscripts retrieved from a previously published systematic review were evaluated. To comprehensively cover the last 25 years, an updated literature search was conducted, screening PubMed, Scopus, and Cochrane databases. Review Methods: We included studies that reported treatment modalities and the time to treatment (TT) for AS/AD, with outcomes objectively evaluated. Data on treatment success were pooled, and the impact of TT on recovery outcomes was analyzed. Results: Thirteen studies involving 361 patients were included. The majority of cases were attributed to iatrogenic trauma following intubation. Closed reduction (CR) was the primary treatment, with high success rates for both general (success rate: 77%, CI: 62–87%) and local anesthesia (success rate: 89%, CI: 70–97%). The standardized mean difference for the TT effect on treatment outcome was −1.24 (CI: −2.20 to −0.29). Conclusions: The absence of randomized controlled trials and the overall moderate-to-low quality of the studies highlighted the importance of the finding’s careful interpretation. This meta-analysis underscores the effectiveness of CR in managing AS/AD, with both general and local anesthesia yielding high success rates. The findings highlight the importance of TT, suggesting that early intervention is paramount. Future clinical research is needed to further refine these findings and optimize treatment protocols. Full article
(This article belongs to the Special Issue Update on Otorhinolaryngologic Diseases (2nd Edition))
Show Figures

Figure 1

Figure 1
<p>PRISMA diagram from identification to inclusion.</p>
Full article ">Figure 2
<p>Forest plot showing pooled outcomes of closed reduction under general anesthesia [<a href="#B14-medicina-61-00092" class="html-bibr">14</a>,<a href="#B15-medicina-61-00092" class="html-bibr">15</a>,<a href="#B16-medicina-61-00092" class="html-bibr">16</a>,<a href="#B17-medicina-61-00092" class="html-bibr">17</a>,<a href="#B24-medicina-61-00092" class="html-bibr">24</a>,<a href="#B27-medicina-61-00092" class="html-bibr">27</a>,<a href="#B28-medicina-61-00092" class="html-bibr">28</a>].</p>
Full article ">Figure 3
<p>Forest plot showing pooled outcomes of closed reduction under local anesthesia [<a href="#B11-medicina-61-00092" class="html-bibr">11</a>,<a href="#B12-medicina-61-00092" class="html-bibr">12</a>,<a href="#B20-medicina-61-00092" class="html-bibr">20</a>,<a href="#B22-medicina-61-00092" class="html-bibr">22</a>,<a href="#B25-medicina-61-00092" class="html-bibr">25</a>,<a href="#B26-medicina-61-00092" class="html-bibr">26</a>].</p>
Full article ">Figure 4
<p>Forest plot showing pooled outcomes of effects of TT on the efficacy of closed reduction [<a href="#B11-medicina-61-00092" class="html-bibr">11</a>,<a href="#B14-medicina-61-00092" class="html-bibr">14</a>,<a href="#B20-medicina-61-00092" class="html-bibr">20</a>,<a href="#B24-medicina-61-00092" class="html-bibr">24</a>].</p>
Full article ">
14 pages, 2686 KiB  
Article
Single Exposure to Low-Intensity Focused Ultrasound Causes Biphasic Opening of the Blood-Brain Barrier Through Secondary Mechanisms
by Tasneem A. Arsiwala, Kathryn E. Blethen, Cullen P. Wolford, Geoffrey L. Pecar, Dhruvi M. Panchal, Brooke N. Kielkowski, Peng Wang, Manish Ranjan, Jeffrey S. Carpenter, Victor Finomore, Ali Rezai and Paul R. Lockman
Pharmaceutics 2025, 17(1), 75; https://doi.org/10.3390/pharmaceutics17010075 - 8 Jan 2025
Viewed by 96
Abstract
Background/Objective: The blood–brain barrier (BBB) is selectively permeable, but it also poses significant challenges for treating CNS diseases. Low-intensity focused ultrasound (LiFUS), paired with microbubbles is a promising, non-invasive technique for transiently opening the BBB, allowing enhanced drug delivery to the central nervous [...] Read more.
Background/Objective: The blood–brain barrier (BBB) is selectively permeable, but it also poses significant challenges for treating CNS diseases. Low-intensity focused ultrasound (LiFUS), paired with microbubbles is a promising, non-invasive technique for transiently opening the BBB, allowing enhanced drug delivery to the central nervous system (CNS). However, the downstream physiological effects following BBB opening, particularly secondary responses, are not well understood. This study aimed to characterize the time-dependent changes in BBB permeability, transporter function, and inflammatory responses in both sonicated and non-sonicated brain tissues following LiFUS treatment. Methods: We employed in situ brain perfusion to assess alterations in BBB integrity and transporter function, as well as multiplex cytokine analysis to quantify the inflammatory response. Results: Our findings show that LiFUS significantly increased vascular volume and glucose uptake, with reduced P-gp function in brain tissues six hours post treatment, indicating biphasic BBB disruption. Additionally, elevated levels of pro-inflammatory cytokines, including TNF-α and IL-6, were observed in both sonicated and non-sonicated regions. A comparative analysis between wild-type and immunodeficient mice revealed distinct patterns of cytokine release, with immunodeficient mice showing lower serum concentrations of IFN-γ and TNF-α, highlighting the potential impact of immune status on the inflammatory response to LiFUS. Conclusions: This study provides new insights into the biphasic nature of LiFUS-induced BBB disruption, emphasizing the importance of understanding the timing and extent of secondary physiological changes. Full article
Show Figures

Figure 1

Figure 1
<p>Vascular and glucose uptake changes 6 h post LIFU. Vascular volume (<b>A</b>) and glucose uptake (<b>B</b>) were significantly increased across the whole brain and within regional distributions (<span class="html-italic">p</span> &lt; 0.01). The error bars represent the standard error of the mean (SEM). Statistical significance is indicated by an asterisk (***).</p>
Full article ">Figure 2
<p>Reduction in P-glycoprotein (P-gp) function 6 h post LIFU. P-gp activity showed a significant decrease in both regional distribution (<b>A</b>) and total brain analyses (<b>B</b>) (<span class="html-italic">p</span> &lt; 0.01). The error bars represent the standard error of the mean (SEM). Statistical significance is denoted by an asterisk (**).</p>
Full article ">Figure 3
<p>Temporal changes in pro-inflammatory cytokine expression post LIFU. The levels of TNF-α, CXCL1, IL-1β, and IL-6 were significantly elevated in the sonicated and contralateral brain regions after 6 h and returned to the baseline at 12 h post sonication (<span class="html-italic">p</span> &lt; 0.01). No significant changes were observed for IL-5, IL-10, IFN-γ, and IL-2 at any of the evaluated time-points.</p>
Full article ">Figure 3 Cont.
<p>Temporal changes in pro-inflammatory cytokine expression post LIFU. The levels of TNF-α, CXCL1, IL-1β, and IL-6 were significantly elevated in the sonicated and contralateral brain regions after 6 h and returned to the baseline at 12 h post sonication (<span class="html-italic">p</span> &lt; 0.01). No significant changes were observed for IL-5, IL-10, IFN-γ, and IL-2 at any of the evaluated time-points.</p>
Full article ">Figure 4
<p>Serum cytokine expression following LIFU: TNF-α, CXCL1, IL-6, and IFN-γ were significantly increased in the serum 6 h post sonication (<span class="html-italic">p</span> &lt; 0.01). No significant differences were observed for IL-10, IL-12p70, IL-4, IL-1β, IL-2, or IL-5 in the serum. Statistical significance is denoted by an asterisk (*, **).</p>
Full article ">Figure 5
<p>Differential cytokine response in wild-type and immunocompromised mice post LIFU: TNF-α and CXCL1 exhibited significant differences in the sonicated and contralateral brain after 6 h in both wild-type (Balb/c) and immunocompromised (Nu/Nu) mice (<span class="html-italic">p</span> &lt; 0.01). In the serum, the TNF-α and IFN-γ levels were also significantly lowered. Some cytokines showed no significant differences between groups in both brain and serum analyses. Statistical significance is denoted by an asterisk (*).</p>
Full article ">Figure 5 Cont.
<p>Differential cytokine response in wild-type and immunocompromised mice post LIFU: TNF-α and CXCL1 exhibited significant differences in the sonicated and contralateral brain after 6 h in both wild-type (Balb/c) and immunocompromised (Nu/Nu) mice (<span class="html-italic">p</span> &lt; 0.01). In the serum, the TNF-α and IFN-γ levels were also significantly lowered. Some cytokines showed no significant differences between groups in both brain and serum analyses. Statistical significance is denoted by an asterisk (*).</p>
Full article ">
21 pages, 2972 KiB  
Review
Dermoscopy of Basal Cell Carcinoma Part 2: Dermoscopic Findings by Lesion Subtype, Location, Age of Onset, Size and Patient Phototype
by Irena Wojtowicz and Magdalena Żychowska
Cancers 2025, 17(2), 176; https://doi.org/10.3390/cancers17020176 - 8 Jan 2025
Viewed by 105
Abstract
Introduction: Basal cell carcinoma (BCC) is the most prevalent type of skin cancer worldwide. Despite its low metastatic potential, certain subtypes present an aggressive clinical course. Part II focuses on the different dermoscopic patterns observed in BCC, depending on the lesion subtype, its [...] Read more.
Introduction: Basal cell carcinoma (BCC) is the most prevalent type of skin cancer worldwide. Despite its low metastatic potential, certain subtypes present an aggressive clinical course. Part II focuses on the different dermoscopic patterns observed in BCC, depending on the lesion subtype, its location on the body, the patient’s age, the size of the tumor, and skin phototype. Methods: A search of the PubMed database was conducted for studies reporting dermoscopic findings in BCC across all body locations, histopathologic subtypes, tumor sizes, ages of onset and skin phototypes. Results: There are no dermoscopic features indicative of a particular BCC subtype. However, arborizing, truncated or glomerular vessels, shiny white lines, ulceration, white areas, absence of pink zones and large blue-gray ovoid nests suggest high-risk BCCs (morpheaform, micronodular, infiltrative, basosquamous). Pigmented features can occur in all BCC types, though increased pigmentation indicates less aggressive subtypes (nodular, superficial, fibroepithelioma of Pinkus, adenoid). BCCs most commonly develop on the head, typically presenting as nodular and non-pigmented tumors. Those on the nose, eyes and ears may be more aggressive and prone to recurrence. On the trunk, BCCs are usually superficial and pigmented. Lower limb lesions often show polymorphous vessels rather than arborizing ones, which makes the dermoscopic diagnosis challenging. Dermoscopy aids early detection, with larger tumors exhibiting more established features but no size-specific patterns. Aggressive subtypes display similar dermoscopic findings regardless of size. Conclusions: Dermoscopy is a valuable tool for the early detection of BCC, though no specific dermoscopic features can definitively identify subtypes. High-risk BCCs can be suspected when distinct vascular and structural patterns are present, particularly in lesions located on the face, especially around the nose, eyes and ears, while pigmented features may indicate less aggressive subtypes. Full article
(This article belongs to the Special Issue Dermoscopy in Skin Cancer)
Show Figures

Figure 1

Figure 1
<p>PRISMA flow chart illustrating the screening procedure.</p>
Full article ">Figure 2
<p>Dermoscopy image of micronodular BCC showing arborizing vessels (red arrows), erosions (green arrowheads), milia-like cyst (yellow arrowheads).</p>
Full article ">Figure 3
<p>Dermoscopy images of nodular BCCs (nBCCs). The nBCC on the left shows arborizing vessels (red arrowhead), blue clod/ovoid nest (green arrowhead), milky way areas (blue asterisks). The nBCC on the right presents arborizing vessels (red arrowhead), multiple gray-blue globules (blue arrowheads), erosions (yellow asterisks), milia-like cyst (yellow circle).</p>
Full article ">Figure 4
<p>Dermoscopy images of superficial basal cell carcinomas (sBCCs). The sBCC on the left shows arborizing vessels (red arrowheads), shiny white areas/blotches (orange asterisks), concentric structures (blue arrows), short fine teleangiectasias (green circle), shiny white lines (yellow arrowheads), multiple in-focus blue/gray dots (yellow circles). The sBCC on the right presents short fine teleangiectasias (yellow circles), erosions (red arrowheads), milky way areas (black asterisks).</p>
Full article ">Figure 5
<p>Dermoscopy images of pigmented BCCs (pBCCs). The pBCC on the left shows multiple gray-blue globules (green arrowheads), arborizing vessel (red arrowhead), blue clods/ovoid nests (blue arrows), multiple in-focus blue/gray dots (yellow circles), milia-like cyst (yellow arrowhead). The pBCC on the right presents erosion (blue arrow), maple-leaf-like areas (red circle), multiple gray-blue globules (red arrowheads), multiple in-focus blue/gray dots (yellow circles), milia-like cyst (green arrowhead), spoke-wheel areas (yellow arrowheads).</p>
Full article ">Figure 6
<p>Dermoscopy images of non-pigmented BCCs. The BCC on the left shows MAY globules (yellow circle), milia-like cysts (blue arrows), arborizing vessel (red arrowhead). The BCC on the right presents arborizing vessels (red arrowheads).</p>
Full article ">Figure 7
<p>Dermoscopy image of BCC located on the shank showing erosion (yellow asterisk), dotted vessels (yellow circle), looped vessels (red circle), glomerular vessels (green circles), milky way areas (black asterisks), brown homogenous blotch (blue arrowhead).</p>
Full article ">Figure 8
<p>Dermoscopy images of BCCs in different sizes. The small BCC on the left shows blue clod/ovoid nest (blue arrow), multiple gray-blue globules (yellow arrowheads), concentric structures (green circle), shiny white line (red arrowheads). The large BCC on the right presents multiple gray-blue globules (green arrowheads), maple-leaf-like areas (red circle), white areas (yellow circle), multiple erosions (blue arrows).</p>
Full article ">
11 pages, 241 KiB  
Review
How to Deal with Pulpitis: An Overview of New Approaches
by Jakub Fiegler-Rudol, Wojciech Niemczyk, Katarzyna Janik, Anna Zawilska, Małgorzata Kępa and Marta Tanasiewicz
Dent. J. 2025, 13(1), 25; https://doi.org/10.3390/dj13010025 - 8 Jan 2025
Viewed by 158
Abstract
Background: Traditional root canal therapy (RCT) effectively removes diseased or necrotic pulp tissue and replaces it with inorganic materials. Regenerative endodontics is an alternative to conventional RCT by using biologically based approaches to restore the pulp–dentin complex. This review explores emerging techniques, including [...] Read more.
Background: Traditional root canal therapy (RCT) effectively removes diseased or necrotic pulp tissue and replaces it with inorganic materials. Regenerative endodontics is an alternative to conventional RCT by using biologically based approaches to restore the pulp–dentin complex. This review explores emerging techniques, including autogenic and allogenic pulp transplantation, platelet-rich fibrin, human amniotic membrane scaffolds, specialized pro-resolving mediators, nanofibrous and bioceramic scaffolds, injectable hydrogels, dentin matrix proteins, and cell-homing strategies. These methods utilize stem cells, growth factors, and biomaterials to regenerate vascularized, functional pulp tissue. Methods: A narrative review was conducted using PubMed, Scopus, and Embase to identify studies published between 2010 and 2023. In vitro, animal, and clinical studies focusing on innovative regenerative endodontic techniques were analyzed. Conclusions: Although regenerative endodontics demonstrates great potential, challenges remain in standardizing protocols, addressing biological variability, and achieving consistent clinical outcomes. Future research must focus on refining these techniques to ensure their safety, efficacy, and accessibility in routine practice. By addressing current limitations, regenerative endodontics could redefine the management of pulpitis, offering biologically based treatments that enhance tooth vitality, structural integrity, and long-term prognosis. Full article
(This article belongs to the Special Issue Endodontics and Restorative Sciences: 2nd Edition)
20 pages, 2666 KiB  
Article
Machine Learning for Lung Cancer Subtype Classification: Combining Clinical, Histopathological, and Biophysical Features
by Aiga Andrijanova, Lasma Bugovecka, Sergejs Isajevs, Donats Erts, Uldis Malinovskis and Andis Liepins
Diagnostics 2025, 15(2), 127; https://doi.org/10.3390/diagnostics15020127 - 7 Jan 2025
Viewed by 271
Abstract
Background/Objectives: Despite advances in diagnostic techniques, accurate classification of lung cancer subtypes remains crucial for treatment planning. Traditional methods like genomic studies face limitations such as high cost and complexity. This study investigates whether integrating atomic force microscopy (AFM) measurements with conventional clinical [...] Read more.
Background/Objectives: Despite advances in diagnostic techniques, accurate classification of lung cancer subtypes remains crucial for treatment planning. Traditional methods like genomic studies face limitations such as high cost and complexity. This study investigates whether integrating atomic force microscopy (AFM) measurements with conventional clinical and histopathological data can improve lung cancer subtype classification. Methods: We developed and analyzed a novel dataset combining clinical, histopathological, and AFM-derived biophysical characteristics from 37 lung cancer patients. Various machine learning techniques were evaluated, with a focus on Bayesian Networks due to their ability to handle complex data with missing values. Leave-One-Out Cross-Validation was employed to assess model performance. Results: The integration of biophysical features improved classification accuracy from 86.49% to 89.19% using a data-driven Bayesian Network model, though this improvement was not statistically significant (p = 1.0). Four key features were identified as highly predictive: sex, vascular invasion, perineural invasion, and ALK mutation. A simplified model using only these features achieved identical performance with significantly reduced complexity (BIC 51.931 vs. 268.586). Conclusions: While AFM-derived measurements showed promise for enhancing lung cancer subtype classification, larger datasets are needed to fully validate their impact. Our findings demonstrate the feasibility of incorporating biophysical measurements into cancer classification frameworks and identify the most predictive features for accurate diagnosis. Further research with expanded datasets is needed to validate these findings. Full article
(This article belongs to the Special Issue Diagnosis and Management of Lung Cancer)
Show Figures

Figure 1

Figure 1
<p>AFM measurement methodology. (<b>a</b>) AFM height image (40 × 40 <math display="inline"><semantics> <mrow> <mi mathvariant="sans-serif">μ</mi> <msup> <mi mathvariant="normal">m</mi> <mn>2</mn> </msup> </mrow> </semantics></math>) of lung adenocarcinoma tissue section; (<b>b</b>) Higher resolution AFM height image (5 × 5 <math display="inline"><semantics> <mrow> <mi mathvariant="sans-serif">μ</mi> <msup> <mi mathvariant="normal">m</mi> <mn>2</mn> </msup> </mrow> </semantics></math>); (<b>c</b>) Corresponding AFM phase image. Similar sequence of images (<b>d</b>–<b>f</b>) shows lung squamous cell carcinoma tissue section measurements.</p>
Full article ">Figure 2
<p>Example of force measurements on individual cancer cell. (<b>a</b>) AFM height image of individual cell with marked measurement points (P0–P7); (<b>b</b>) Optical image showing AFM probe and cells; (<b>c</b>) Force-displacement curves from cytoplasm and nucleus regions with calibration curve.</p>
Full article ">Figure 3
<p>Demographic and clinical characteristics of the study cohort. Distribution of age by cancer subtype; Sex distribution; Smoking history in pack-years; Stage distribution by cancer subtype.</p>
Full article ">Figure 4
<p>Distribution of genetic biomarkers by cancer subtype. Bar plot showing prevalence of EGFR, ALK, ROS1, and NTRK mutations in adenocarcinoma versus squamous cell carcinoma patients.</p>
Full article ">Figure 5
<p>Cell dimension analysis by cancer invasiveness. Cell height measurements comparing invasive versus non-invasive samples; Cell width measurements comparing invasive versus non-invasive samples.</p>
Full article ">Figure 6
<p>Surface roughness analysis. (<b>a</b>) Example of 20 × 20 <math display="inline"><semantics> <mrow> <mi mathvariant="sans-serif">μ</mi> <msup> <mi mathvariant="normal">m</mi> <mn>2</mn> </msup> </mrow> </semantics></math> AFM height image with selected 5 × 5 <math display="inline"><semantics> <mrow> <mi mathvariant="sans-serif">μ</mi> <msup> <mi mathvariant="normal">m</mi> <mn>2</mn> </msup> </mrow> </semantics></math> analysis regions; (<b>b</b>) Corresponding roughness measurements.</p>
Full article ">Figure 7
<p>Cell elasticity measurements by cancer stage. Nucleus region elasticity comparison between early and late stage samples; Cytoplasm region elasticity comparison between early and late stage samples. Early stage samples show significantly lower elasticity in both regions (Mann-Whitney U test, <span class="html-italic">p</span> &lt; 0.05).</p>
Full article ">Figure 8
<p>Receiver Operating Characteristic (ROC) curves for Bayesian Network models using all features. The blue curve represents the model with learned structure, while the orange curve represents the model with inferred structure. The area under each curve (AUC) provides a measure of the model’s overall performance.</p>
Full article ">Figure 9
<p>Confusion matrices for the Bayesian Network models using all features. (<b>a</b>) Model without biophysical features. (<b>b</b>) Model with biophysical features. The matrices illustrate the classification performance of each model in terms of true positives, true negatives, false positives, and false negatives.</p>
Full article ">
21 pages, 2529 KiB  
Article
Increased Oxidative and Nitrative Stress and Decreased Sex Steroid Relaxation in a Vitamin D-Deficient Hyperandrogenic Rodent Model—And a Validation of the Polycystic Ovary Syndrome Model
by Réka Eszter Sziva, Réka Kollarics, Éva Pál, Bálint Bányai, Ágnes Korsós-Novák, Zoltán Fontányi, Péter Magyar, Anita Süli, György L. Nádasy, Nándor Ács, Eszter Mária Horváth, Leila Hadjadj and Szabolcs Várbíró
Nutrients 2025, 17(2), 201; https://doi.org/10.3390/nu17020201 - 7 Jan 2025
Viewed by 351
Abstract
Background/Objectives: Both hyperandrogenism (HA) and vitamin D deficiency (VDD) can separately lead to impaired vascular reactivity and ovulatory dysfunction in fertile females. The aim was to examine the early interactions of these states in a rat model of PCOS. Methods: Four-week-old adolescent female [...] Read more.
Background/Objectives: Both hyperandrogenism (HA) and vitamin D deficiency (VDD) can separately lead to impaired vascular reactivity and ovulatory dysfunction in fertile females. The aim was to examine the early interactions of these states in a rat model of PCOS. Methods: Four-week-old adolescent female rats were divided into four groups: vitamin D (VD)-supplemented (n = 12); VD-supplemented and testosterone-treated (n = 12); VDD- (n = 11) and VDD-and-testosterone-treated (n = 11). Animals underwent transdermal testosterone treatment for 8 weeks. Target VD levels were achieved with oral VD supplementation and a VD-free diet. Estrous cycles were followed by vaginal smear, and quantitative histomorphometric measurements of the ovaries were also taken. In the 8th week, testosterone- and estrogen-induced relaxation of coronary arterioles was examined with pressure angiography. Estrogen receptor (ER) density and oxidative and nitrative stress parameters (Poly-(ADP-Ribose)-Polymerase and 3-nitrotyrosine) in the vessel wall were investigated with immunohistochemistry. Results: VDD caused impaired estrous cycles, and testosterone caused anovulatory cycles (the cycles were stopped at the diestrous phase). VDD combined with testosterone treatment resulted in reduced testosterone and estrogen vasorelaxation, lower ER density, and higher oxidative and nitrative stress in the vessel wall. Conclusions: PCOS with vitamin D deficiency may be associated with increased oxidative–nitrative stress in coronary arterioles. This oxidative and nitrative stress, potentially caused by hyperandrogenism and/or vitamin D deficiency, could impair estrogen-induced relaxation of the coronary arterioles, possibly by decreasing NO bioavailability and disrupting the estrogen-induced relaxation pathway. Full article
(This article belongs to the Special Issue Impact of Diet, Nutrition and Lifestyle on Reproductive Health)
Show Figures

Figure 1

Figure 1
<p>Representative hematoxylin–eosin-stained histological sections demonstrate the characteristic ovary morphology of each group. Only the VD+/T− animals showed normal follicle development and a normal number of corpora lutea. Polycystic ovary morphology was detectable after transdermal testosterone treatment. Interestingly, VD deficiency caused similar changes and led to an elevated number of non-dominant (primordial) follicles. VD+/T−: vitamin D3-supplemented; VD+/T+: vitamin D3-supplemented and transdermal testosterone-treated; VD−/T−: vitamin D3-deficient; and VD−/T+: vitamin D3-deficient and transdermal testosterone-treated.</p>
Full article ">Figure 2
<p>TXA<sub>2</sub> agonist (U46619)-induced full contraction and sexual steroid-induced relaxation of the coronary arterioles (results are shown in mean ± SEM). (<b>a</b>) Inner radius in full contraction (after potent vasoconstrictive agent U46619) state as a function of intraluminal pressure. No difference in contractile capacity was observed between the two vitamin D-supplemented groups, both of which exhibited significantly higher values compared to the vitamin D-deficient groups (<span class="html-italic">p</span> &lt; 0.05 in both comparisons). There was no difference in contractile capacity among the vitamin D-deficient groups. Both VD-deficient groups, regardless of transdermal T treatment, had significantly reduced contraction capacities compared to both VD-supplemented groups (†: <span class="html-italic">p</span> &lt; 0.01, VD+/T− vs. VD−/T+ and VD+/T+ vs. VD−/T−). (<b>b</b>) Percent of vessel tone on fixed intraluminal pressure (50 mmHg) after administering an elevated dose of 17-beta estradiol. At higher 17-beta estradiol concentration values, the VD-deficient, transdermal T-treated group had significantly lower values compared to the VD-supplemented transdermal T-free group (†: <span class="html-italic">p</span> &lt; 0.01 and <span class="html-italic">p</span> &lt; 0.001 on elevated doses for VD−/T+ vs. VD+/T−). The VD-supplemented T-treated group showed similar concentration-dependent tone changes compared to the VD-supplemented non-T-treated group (*: <span class="html-italic">p</span> &lt; 0.01 for VD+/T+ vs. VD+/T−). Significant tone reduction was detected among VD-deficient arterioles on the highest applied concentration (‡: <span class="html-italic">p</span> &lt; 0.01 for VD−/T− vs. VD+/T−). (<b>c</b>) Percent of vessel tone on fixed intraluminal pressure (50 mmHg) after administering an elevated dose of testosterone. The VD-supplemented, transdermal T-free group showed significantly higher relaxation capacities compared to all other groups (‡: <span class="html-italic">p</span> &lt; 0.001 on each dose for VD+/T− vs. VD+/T+, VD−/T−, and VD−/T+). Abbreviations: VD+/T−: vitamin D-supplemented; VD+/T+: vitamin D-supplemented and transdermal testosterone-treated; VD−/T−: vitamin D-deficient; VD−/T+: vitamin D-deficient and transdermal testosterone-treated; and M: drug concentration in mol/L applied in the organ chamber. <span class="html-italic">n</span> = 11 in all groups. The significance of the two-way ANOVA tests is shown. All values are expressed in mean ± SEM.</p>
Full article ">Figure 3
<p>Immunohistochemical examination of estrogen receptor beta (ERB) specific immunostaining positivity across the vessel wall. Positively stained tissue area compared to total tissue area of the endothelial (<b>a</b>) and media layers (<b>b</b>). A significantly lower estrogen receptor density was observed in all examined layers if any of the two noxae were presented (<span class="html-italic">p</span> &lt; 0.01 in all comparisons). The values are in total area ratio percentages; <span class="html-italic">n</span> = 6 in all groups. VD+/T−: vitamin D-supplemented; VD+/T+: vitamin D-supplemented and transdermal testosterone-treated; VD−/T−: vitamin D-deficient; VD−/T+: vitamin D-deficient and transdermal testosterone-treated; and ERB: estrogen receptor beta. The significance of the one-way ANOVA tests is shown above the bars. All values are expressed in mean ± SEM.</p>
Full article ">Figure 4
<p>Poly(ADP-ribose) (PAR) formation in the ovarian tissue (<b>a</b>) and the vessel wall (<b>b</b>). In the ovary samples, no significant difference in the PAR-positive nuclear area ratio was detected between the four groups. The coronary arterioles of the VD-supplemented transdermal T-free animals had the lowest detected PARP activity (<span class="html-italic">p</span> &lt; 0.01 in all comparisons). The values are in total nuclear area ratio percentages; <span class="html-italic">n</span> = 6 in all groups. VD+/T−: vitamin D-supplemented; VD+/T+: vitamin D-supplemented and transdermal testosterone-treated; VD−/T−: vitamin D-deficient; and VD−/T+: vitamin D-deficient and transdermal testosterone-treated. The significance of the one-way ANOVA tests is shown above the bars. All values are expressed in mean ± SEM.</p>
Full article ">Figure 5
<p>Expression of 3-nitrotyrosine formation in the vessel wall: (<b>a</b>) endothelium, (<b>b</b>) media layer. Regarding endothelial activity, the VD-deficient, T-treated group showed a significant increase in 3-nitrotyrosine-specific immunostaining positivity compared to the other groups <span class="html-italic">(p</span> &lt; 0.01 and <span class="html-italic">p</span> &lt; 0.05, respectively). In the media layer, the VD-deficient, T-free animals had significantly higher values than all other groups <span class="html-italic">(p</span> &lt; 0.01 and <span class="html-italic">p</span> &lt; 0.001); however, the VD-deficient, T-treated animals had significantly increased staining compared to both VD-supplemented groups (<span class="html-italic">p</span> &lt; 0.01). The values are in total area ratio percentages; <span class="html-italic">n</span> = 6 in all groups. VD+/T−: vitamin D-supplemented; VD+/T+: vitamin D-supplemented and transdermal testosterone-treated; VD−/T−: vitamin D-deficient; and VD−/T+: vitamin D-deficient and transdermal testosterone-treated. The significance of the one-way ANOVA tests is shown above the bars. All values are expressed in mean ± SEM.</p>
Full article ">
Back to TopTop